Steven Gunstream, CEO, discusses the impact of FDA changes on cell and gene therapy demand, revenue trends per customer, and the competitive position of the collaboration with Pluralistics in the earnings call. The company anticipates growth despite challenges in the biotech funding landscape.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing